Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Metastatic Castration-Resistant Prostate Cancer (mCRPC), characterized by its lengthy disease trajectory and diverse clinical outcomes among individual patients, predominantly affects men aged 45 to 60. Risk factors associated with this cancer encompass familial predisposition, ethnicity, age, obesity, and various environmental influences, with familial inheritance being a significant genetic risk factor. The majority of newly diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) cases initially present with localized disease, typically managed through radical prostatectomy and radiation therapy, followed by androgen deprivation therapy (ADT). However, within a decade, a variable percentage of patients progress to castration-resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) (CRPC). Among them, those with metastatic castration-resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MCRPC) face a particularly grim prognosis, with median survival ranging from 9 to 30 months for CRPC and reduced to 9–13 months for MCRPC. Current therapeutic strategies for MCRPC include cytotoxic chemotherapy agents, androgen receptor (AR) blocking agents, immunotherapies, and radiopharmaceuticals, with taxane chemotherapy (such as docetaxel and cabazitaxel) being the standard treatment.

·       In the USA, the incidence of Metastatic Castration-Resistant Prostate Cancer (mCRPC) ranges from 95 to 112 cases per 100,000 population, constituting approximately 15% of all cancer diagnoses. Notably, 85% to 90% of cases of newly developed MCRPC stem from the progression of non-metastatic castration-resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) (nmCRPC).

 

Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Metastatic Castration-Resistant Prostate Cancer (mCRPC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) market outlook, Metastatic Castration-Resistant Prostate Cancer (mCRPC) competitive landscape, Metastatic Castration-Resistant Prostate Cancer (mCRPC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more